(WLLW) – PRNewswire
-
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF
-
WILLOW BIOSCIENCES ANNOUNCES SECOND STRATEGIC INVESTMENT FROM KALSEC
-
WILLOW BIOSCIENCES ANNOUNCES STRATEGIC INVESTMENT FROM KALSEC TO DEVELOP INNOVATIVE NATURAL FOOD INGREDIENTS
-
WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
-
WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
-
WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023
-
WILLOW AND LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY ADVANCE DEVELOPMENT PROGRAM TO MANUFACTURE SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
-
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
-
WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING
-
WILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API THROUGH PRECISION FERMENTATION
-
WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED UDCA
-
WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL TRANSITION AND FOCUS ON BIOOXI PLATFORM
-
WILLOW ANNOUNCES COLLABORATION WITH A LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
-
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS
-
WILLOW BIOSCIENCES TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON AUGUST 9
-
WILLOW AND KALSEC ADVANCE DEVELOPMENT PROGRAM FOR NEW NATURAL FUNCTIONAL INGREDIENT FOR SAVORY FOODS
-
WILLOW BIOSCIENCES TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON JUNE 14
-
WILLOW SIGNS MASTER SERVICES AGREEMENT WITH INNOVATIVE BIOTECH COMPANY TO DEVELOP INGREDIENTS FOR AGE-RELATED DISEASES
-
KALSEC AND WILLOW BIOSCIENCES TO DEVELOP NOVEL ENZYME FOR PRODUCTION OF AN ADVANCED BEVERAGE INGREDIENT
-
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2023 RESULTS
-
WILLOW ANNOUNCES COMMERCIAL AGREEMENT WITH SANDHILL ONE
-
WILLOW ANNOUNCES ROLLOUT OF BioOxi PLATFORM PROVIDING VALUABLE AND EXPEDITED BIOCONVERSION-ENABLED CHEMICAL MANUFACTURING
-
WILLOW BIOSCIENCES ANNOUNCES CHANGES TO BOARD AND MANAGEMENT
-
WILLOW & SUANFARMA ANNOUNCE COMPLETED DEVELOPMENT AND MANUFACTURING PROCESS FOR CBG AND COMMITMENT TO THE PRODUCTION OF NEW MOLECULES IN A NATURAL WAY
-
WILLOW ANNOUNCES APPOINTMENT OF DR. JIM LALONDE TO BOARD OF DIRECTORS
-
WILLOW ANNOUNCES FOLLOW-ON ENGAGEMENT FOR NEXT PHASE OF PARTNERED PHARMACEUTICAL PROJECT
-
WILLOW PROVIDES CORPORATE UPDATES, BUSINESS OUTLOOK AND KEY TARGETED MILESTONES ANTICIPATED FOR 2023 TO EXPAND GROWTH
-
WILLOW FURTHER OPTIMIZES ITS BUSINESS TO FOCUS ON NEAR-TERM REVENUE GENERATION AND REDUCE CASH BURN
-
KALSEC SIGNS MASTER SERVICES AGREEMENT WITH WILLOW BIOSCIENCES FOR THE DEVELOPMENT AND MANUFACTURE OF FUNCTIONAL FOOD INGREDIENTS USING PRECISION FERMENTATION
-
WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST
-
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2022 RESULTS AND ANNOUNCES APPOINTMENT OF DR SEUFER-WASSERTHAL AS PRESIDENT AND CEO
-
WILLOW BIOSCIENCES ANNOUNCES NEW FUNCTIONAL INGREDIENT ASTAXANTHIN ADDED TO PRODUCT PORTFOLIO
-
WILLOW BIOSCIENCES PROVIDES CBG UPDATE
-
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2022 RESULTS
-
WILLOW BIOSCIENCES APPOINTS DR. PETER SEUFER-WASSERTHAL AS INTERIM PRESIDENT AND CEO
-
WILLOW BIOSCIENCES INCORPORATES INSCRIPTA'S ONYX® PLATFORM TO EXPAND STRAIN ENGINEERING CAPABILITIES AND THROUGHPUT
-
WILLOW BIOSCIENCES EXPANDS ITS PORTFOLIO WITH A NEW PARTNERED PHARMACEUTICAL PROJECT
-
WILLOW BIOSCIENCES ANNOUNCES EXPANSION OF ITS FERMENTATION MANUFACTURING NETWORK AND PROGRESS ON ITS CBG GRAS DETERMINATION
-
WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST
-
WILLOW BIOSCIENCES PUBLISHES THE FIRST PEER REVIEWED ARTICLE DEMONSTRATING THE CLINICAL BENEFIT OF CBG FOR SKINCARE
-
Willow Biosciences Reports Third Quarter 2021 Results
-
Willow Biosciences Announces Commercial Scale Operational Update, CBGA Production Update and Corporate Update
-
Willow Biosciences Announces Expansion of its Commercial Operations Team and Development Portfolio, an Update on its Intellectual Property Position, and Formation of ESG Committee
-
Willow Biosciences and Cellular Goods Announce Multiyear Supply Agreement for Cannabigerol (CBG)
-
Willow Biosciences Announces Participation In Synbiobeta Panel Discussion
-
Willow Biosciences Added to NYSE-Listed Cannabis ETF "THCX"
-
Willow Biosciences Announces Ground-Breaking Scientific Data for Cannabigerol (CBG) on Human Skin
-
Willow Biosciences Announces Completion of its First Commercial Scale Fermentation Run
-
Willow Biosciences Announces Exercise of Over-Allotment Option and Completion of Previously Announced Bought Deal Offering
-
Willow Biosciences Announces Acceleration of Expiry Date of Outstanding Warrants Issued Pursuant to October 2020 Unit Financing
Back to WLLW Stock Lookup
